glp-1/gip dual agonist lilly Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage clinical trial, the company announced. In Eli Lilly and phase results

While results can vary and more human studies are needed to validate many of the claims surrounding BPC-157, the early feedback and preclinical research suggest promising directionsespecially when it comes to natural recovery, resilience, and performance support

The kidney is an important site for in vivo phenylalanine-to-tyrosine conversion in adult humans: a metabolic role of the kidney

Marketing glutathione for skin whitening, detoxification, or disease treatment without FDA approval violates federal lawthe legality hinges on formulation, administration route, and therapeutic claims made

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

While these products are often marketed as GLP-1 patches or needle-free alternatives, theyre fundamentally different from medical treatments